A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (TPH1) for treating peripheral serotonin related diseases or disorders

摘要

19.05 ± 0.20 θ） (E) - ethyl 8 - (2-amino-6 - (R) - 1 -) shows an XRPD pattern having a characteristic peak in (5 - chloro - [1,1 - biphenyl] - 2-yl) - 2,2,2-trifluoroethoxy) pyrimidine-4-yl) - crystalline compound of 2,8-diazopyriro [4.5] decan-3 carboxylate.There is also a pharmaceutical composition comprising the compound.There is also a dosage form that includes the crystalline compound and pharmaceutically acceptable excipients.There is also a method for crystallizing / recrystallizing the compound.There is also a method for treating or preventing a disease with said compound.